By Fineline Cube China’s National Drug Joint Procurement Office released enterprise-related information for the 12th batch of national organized volume-based drug procurement, setting the stage for one of the country’s largest pharmaceutical tendering events to date.
Procurement Overview
| Item | Detail |
|---|---|
| Agency | National Drug Joint Procurement Office |
| Procurement Round | 12th batch of national organized volume-based procurement |
| Release Date | 28 Jul 2026 |
| Expected Participants | Over 500 pharmaceutical enterprises |
| Total Estimated Demand | Approximately 7.34 billion units/doses |
| Next Steps | Bidding process to commence in coming weeks |
Market Participation & Scale
- Participation: More than 500 pharmaceutical companies are expected to submit bids, representing both domestic manufacturers and multinational corporations with operations in China.
- Demand Volume: The procurement round covers an estimated 7.34 billion units or doses across multiple therapeutic categories, making it one of the largest single procurement events in China’s healthcare system.
- Strategic Importance: Participation in China’s volume-based procurement program has become essential for pharmaceutical companies seeking sustainable market access, despite significant price reductions typically required to win contracts.
Historical Context & Program Impact
China’s national drug procurement initiative, launched in 2018, has fundamentally reshaped the country’s pharmaceutical landscape by leveraging bulk purchasing power to negotiate substantial price reductions while ensuring stable supply to hospitals nationwide. Previous rounds have achieved average price cuts of 50-60% compared to pre-procurement levels, significantly improving affordability for patients while maintaining quality standards through stringent qualification requirements.
The 12th batch continues this strategy of using China’s enormous patient population as negotiating leverage, with participating companies required to meet rigorous quality and supply capacity criteria to be eligible for bidding.
Market Implications
- Revenue Impact: Winning bidders secure guaranteed volume contracts with China’s vast public hospital network, offsetting lower per-unit prices through scale.
- Market Consolidation: The program has accelerated industry consolidation, with smaller manufacturers struggling to meet quality and scale requirements.
- Innovation Balance: Recent procurement rounds have begun incorporating innovative drugs alongside generics, signaling a shift toward balancing cost containment with therapeutic advancement.
Forward‑Looking Statements
This brief contains forward-looking statements regarding China’s drug procurement program. Actual participation, bidding outcomes, and market impacts may differ due to regulatory changes, competitive dynamics, and implementation challenges.-Fineline Info & Tech